Pharsight

Qinlock is owned by Deciphera Pharms.

Qinlock contains Ripretinib.

Qinlock has a total of 10 drug patents out of which 0 drug patents have expired.

Qinlock was authorised for market use on 15 May, 2020.

Qinlock is available in tablet;oral dosage forms.

Qinlock can be used as treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib, treatment of gastrointestinal stromal tumors in patients being treated concurrently with a cyp3a4 inhibitor, treatment of gastrointestinal stromal tumor, treatment of gastrointestinal stromal tumors in patients suffering from palmer-planter erythrodysesthesia syndrome, method of treating gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 myalgia while being administered ripretinib daily, treatment of gastrointestinal stromal tumors in patients suffering from hypertension.

Drug patent challenges can be filed against Qinlock from May, 2024.

The generics of Qinlock are possible to be released after 30 December, 2040.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188113	DECIPHERA PHARMS	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases	Jul, 2030 (7 years from now)
US8461179	DECIPHERA PHARMS	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases	Jun, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48731	DECIPHERA PHARMS	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases	Jun, 2032 (9 years from now)
US11266635	DECIPHERA PHARMS	Methods of treating gastrointestinal stromal tumors	Aug, 2040 (17 years from now)
US10966966	DECIPHERA PHARMS	Methods of treating gastrointestinal stromal tumors	Aug, 2040 (17 years from now)
US11433056	DECIPHERA PHARMS	Methods of treating gastrointestinal stromal tumors	Aug, 2040 (17 years from now)
US11344536	DECIPHERA PHARMS	Methods of treating gastrointestinal stromal tumors	Aug, 2040 (17 years from now)
US11426390	DECIPHERA PHARMS	Methods of treating gastrointestinal stromal tumors	Aug, 2040 (17 years from now)
US11185535	DECIPHERA PHARMS	Amorphous kinase inhibitor formulations and methods of use thereof	Dec, 2040 (17 years from now)
US11395818	DECIPHERA PHARMS	Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea	Dec, 2040 (17 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 15, 2025
Orphan Drug Exclusivity (ODE)	May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of gastrointestinal stromal tumor; Treatment of gastrointestinal stromal tumors in patients suffering from palmer-planter erythrodysesthesia syndrome; Treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib; Method of treating gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 myalgia while being administered ripretinib daily; Treatment of gastrointestinal stromal tumors in patients suffering from hypertension; Treatment of gastrointestinal stromal tumors in patients being treated concurrently with a cyp3a4 inhibitor

Dosage: TABLET;ORAL